Solara Active Pharma Sciences Limited , a prominent player in the pharmaceutical industry, has made significant moves in its employee incentive programs. The company's Board of Directors recently approved the allotment of 8,040 equity shares under the Solara Employee Stock Option Plan 2018.

Key Details of the Stock Option Allotment

• Number of Shares Allotted: 8,040 equity shares
• Face Value: Rs. 10 each
• Allotment Date: November 5, 2025
• Funds Raised: Rs. 30,15,000 from the exercise of these options

Impact on Share Capital

• Previous Paid-up Capital: Rs. 44,47,93,723.50
• New Paid-up Capital: Rs. 44,48,74,123.50
• Previous Number of Fully Paid Equity Shares: 3,61,63,267
• New Number of Fully Paid Equity Shares: 3,61,71,307

The newly allotted shares rank pari-passu with existing equity shares.

Financial Impact

• Diluted Earnings Per Share: Rs. 19.00 per share

This allotment follows a previous grant of stock options to employees:

Previous Stock Option Grant

• Number of Options Granted: 25,000 stock options
• Exercise Price: Rs. 375.00 per equity share
• Vesting Schedule:

  Year	Percentage of Options Vested
  First Year	20.00%
  Second Year	30.00%
  Third Year	50.00%

• Minimum Vesting Period: One year from the grant date
• Exercise Period: 120 days from the vesting date

These stock options are designed to align employee interests with those of the company and its shareholders, potentially enhancing motivation and retention of key talent.

Financial Context

Solara Active Pharma Sciences reported a loss of Rs. 10.10 crores for the quarter ended September 30, with accumulated losses of Rs. 314.25 crores. However, the company is taking steps to strengthen its financial position, including:

• Expecting to raise Rs. 134.99 crores through the pending final call of its rights issue
• Focusing on increasing revenues and margins on its products
• Anticipating renewal of working capital facilities as needed

Corporate Developments

Solara is also undergoing structural changes:

• The company is exploring the demerger of its CRAMS (Contract Research and Manufacturing Services) and Polymers business into an independent listed entity
• A new wholly-owned subsidiary, Synthix Global Pharma Solutions Limited, was incorporated on April 29 as part of this restructuring process

Despite short-term challenges, Solara Active Pharma Sciences appears to be taking strategic steps to align employee incentives with company performance and shareholder interests, while also restructuring its business for potential future growth.

Solara Active Pharma Sciences Limited , a prominent player in the Active Pharmaceutical Ingredient (API) sector, has announced significant changes to its board composition, senior management team, and key appointments.

Board Reshuffle and Committee Reconstitution

The company reported that Mr. Kartheek Chintalapati Raju has stepped down from his position as Non-Executive Director, citing preoccupation and personal commitments. Consequently, he has also relinquished his roles in the Stakeholders Relationship Committee and Nomination and Remuneration Committee.

In response to these changes, Solara Active Pharma Sciences has reconstituted its board committees:

Stakeholders Relationship Committee:

Nomination and Remuneration Committee:

The company expressed its appreciation for Mr. Raju's contributions during his tenure.

New Chief Human Resources Officer Appointed

Solara Active Pharma Sciences has appointed Mr. Mohanraj S as the new Chief Human Resources Officer (CHRO) and designated him as Senior Management Personnel. The appointment was approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee.

Mr. Mohanraj brings over 30 years of cross-industry experience to the role, with expertise spanning Pharma, Biotech, Engineering, Aerospace, Apparel, and Media sectors. His career includes leadership positions at Mylan Laboratories, The Manipal Group, and Tata Advanced Materials. His areas of expertise encompass Talent Management, Employee Relations, Organizational Development, HRIS, and Digital Transformation.

Mr. Mohanraj holds a Masters in Social Work (HRM) from Madras University and a BA in Behavioural Sciences from St. Josephs College, Bangalore. He is also a certified ISO auditor and has served on the Board of Studies for Industrial Relations at St. Josephs University for two decades.

As Solara's HR head, Mr. Mohanraj will be responsible for leading people strategy, culture transformation, and governance to align HR with the company's long-term business goals.

Additional Management Changes and Remuneration Revisions

The Board of Directors has made several other key decisions:

1. Mr. Sarat Kumar Asuri, the current Chief Financial Officer, has been appointed to the additional role of Chief Investor Relations Officer.

2. The Board approved a revision in remuneration for Whole-time Director Mohan Muthunarayanan. This revision is within the previously approved shareholder limits and aligns with the company's remuneration policy guidelines.

3. Remuneration for eligible Senior Management Personnel has been revised.

4. The company's existing Risk Management Policy was reviewed and confirmed.

These changes reflect Solara Active Pharma Sciences' commitment to strengthening its leadership structure and aligning management incentives with company performance and shareholder interests.